Navigation Links
EntreMed Announces Publication Of Preclinical Results For ENMD-2076 In Triple-negative Breast Cancer
Date:11/26/2012

selection, and may increase the probability of success. We are continuing to enroll patients in the ongoing Phase 2 trial and anticipate the initiation of a second site for this trial soon. We remain on track with our clinical development activities and expect our progress to accelerate in the coming months and year."

About EntreMed

EntreMed, Inc. is a clinical-stage pharmaceutical company employing a drug development strategy primarily in the United States and China to develop targeted therapeutics for the global market.  Its lead compound, ENMD-2076, a selective angiogenic kinase inhibitor, has completed several Phase 1 studies in solid tumors, multiple myeloma, and leukemia, and is currently completing a multi-center Phase 2 study in ovarian cancer. EntreMed, Inc. recently initiated a Phase 2 study of ENMD-2076 in triple-negative breast cancer.  Additional information about EntreMed is available on the Company's website at www.entremed.com and in various filings with the Securities and Exchange Commission (the SEC).

About ENMD-2076

ENMD-2076 is an orally-active, Aurora A/angiogenic kinase inhibitor with a unique kinase selectivity profile and multiple mechanisms of action. ENMD-2076 has been shown to inhibit a distinct profile of angiogenic tyrosine kinase targets in addition to the Aurora A kinase. Aurora kinases are key regulators of mitosis (cell division), and are often over-expressed in human cancers. ENMD-2076 also targets the VEGFR, Flt-3 and FGFR3 kinases which have been shown to play important roles in the pathology of several cancers. ENMD-2076 has shown promising activity in Phase 1 clinical trials in solid tumor cancers, leukemia, and multiple myeloma. ENMD-2076 is currently completing a Phase 2 trial for ovarian cancer.  EntreMed, Inc. recently initiated a Phase 2 study of ENMD-2076 in triple-negative breast cancer.

Forward Looking Statements   &#
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Dana-Farber Cancer Institutes Ursula A. Matulonis, MD Article on EntreMeds ENMD-2076 Published in the European Journal of Cancer
2. EntreMed Reports Second Quarter 2012 Financial Results
3. EntreMed Announces Initiation Of Phase 2 Trial In Triple-negative Breast Cancer
4. EntreMed Reports First Quarter 2012 Financial Results
5. Trovagene Announces Closing of Private Placement of $3.76 Million from the Sale of Restricted Common Stock and Warrants
6. ResMed Inc. Announces Exchange Rate For Upcoming Dividend Payment
7. AspenBio Pharma Announces Closing of Public Offering of 1,946,000 Shares of Common Stock
8. Vasomedical Announces Financial Results for the Third Quarter of 2012
9. Proteonomix, Inc. Announces Screening of Patients with End Stage Liver Disease in its Clinical Study of UMK-121
10. Ohr Pharmaceutical Announces Additions to Ophthalmic Scientific Advisory Board
11. NeuroDerm Announces Enrollment in a Phase 1 Study of ND0612, a Continuous Levodopa/Carbidopa Drug for the Treatment of Parkinsons Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)...   MultiVir Inc. ("MultiVir"), a clinical-stage gene ... for the treatment of multiple oncological indications, today announced ... Form S-1 with the U.S. Securities and Exchange Commission ... shares of its common stock. The number of shares ... proposed offering have not yet been determined. MultiVir has ...
(Date:3/30/2015)... Sorrento Therapeutics, Inc. (Nasdaq: SRNE ) ... to the position of Executive Vice President & ... be responsible for all legal, compliance and intellectual property ... BioDelivery Sciences International, Inc., where he was Senior Vice ... management that led that company to over a six ...
(Date:3/30/2015)... Mass. , March 30, 2015 Alere ... rapid diagnostics, issued the following statement today in support ... to Combat Antibiotic-Resistant Bacteria. "As the ... commend President Barack Obama for establishing a ... to address the serious threat of antibiotic resistance. We ...
Breaking Medicine Technology:MultiVir Files Registration Statement for Proposed Initial Public Offering 2Sorrento Announces Appointment Of George Ng As EVP & Chief Legal Officer 2Sorrento Announces Appointment Of George Ng As EVP & Chief Legal Officer 3Alere Applauds President's National Action Plan to Combat Antibiotic-Resistant Bacteria 2
... 19, 2007 /PRNewswire-FirstCall/ --,Allos Therapeutics, Inc. today ... with a favorable opinion of the Committee ... Agency (EMEA),has granted orphan drug designation to ... treatment of patients with,peripheral T-cell lymphoma (PTCL). ...
... -- Median time to pain progression is 66.1 ... for the placebo arm --,Hazard ratio of 0.64 ... the relative risk of pain progression, MARTINSRIED/MUNICH, Germany, ... Colo. -- GPC Biotech AG and,Pharmion Corporation today ...
Cached Medicine Technology:Allos Therapeutics' PDX Granted Orphan Medicinal Product,Designation by the European Commission 2Allos Therapeutics' PDX Granted Orphan Medicinal Product,Designation by the European Commission 3Allos Therapeutics' PDX Granted Orphan Medicinal Product,Designation by the European Commission 4Additional Efficacy Data from Satraplatin SPARC Phase 3,Investigational Trial Presented at Annual Meeting of American,Urological Association 2Additional Efficacy Data from Satraplatin SPARC Phase 3,Investigational Trial Presented at Annual Meeting of American,Urological Association 3Additional Efficacy Data from Satraplatin SPARC Phase 3,Investigational Trial Presented at Annual Meeting of American,Urological Association 4Additional Efficacy Data from Satraplatin SPARC Phase 3,Investigational Trial Presented at Annual Meeting of American,Urological Association 5Additional Efficacy Data from Satraplatin SPARC Phase 3,Investigational Trial Presented at Annual Meeting of American,Urological Association 6
(Date:3/30/2015)... Good Shepherd Children’s Home announces 53rd year of caring for ... Christian-based home, the children learn biblical principles and are taught ... their life. , A day in the life… , ... children begin to awake and prepare for the day ahead. ... Sleepily, she crawls out of bed and scrambles to ...
(Date:3/30/2015)... (PRWEB) March 31, 2015 Healtheminds, a ... wellness services through an innovative, easy to use and ... to create awareness about mental health related issues. The ... addiction to alcohol, tobacco and other drugs. , ... adverse health effects. These include the toxic effects of ...
(Date:3/30/2015)... 30, 2015 Zane Benefits, the ... businesses, announced its latest webinar "Can Tax-Free Premium ... This discussion was conducted by Zane Benefits ... Benefits, there is a massive transition to employer-funded ... selecting a group health plan, employers are now ...
(Date:3/30/2015)... Textile Exchange, a global nonprofit dedicated to sustainability ... latest version of its Responsible Down Standard (RDS) ... applied to any waterfowl-based supply chain to help ensure ... The goal of the RDS is to recognize and ... traceability so that products can be labeled accurately and ...
(Date:3/30/2015)... March 30, 2015 Healthy, radiant skin ... Pharmacy. The staff of pharmacists is specially trained and ... like acne, eczema and other conditions. , Most people ... patient’s dermatologist and/or PCP to tackle most skin conditions ... Pharmacy has employed specialty-trained pharmacists who have experience in ...
Breaking Medicine News(10 mins):Health News:Good Shepherd Children’s Home Announces 53rd Year of Providing a Safe-Haven for Children in Need 2Health News:HealthEminds Launching Webinar on Drug Dependence 2Health News:Zane Benefits New Webinar Premium Reimbursement Webinar Now Available On-Demand 2Health News:Responsible Down Standard 2.0 Released 2Health News:Responsible Down Standard 2.0 Released 3Health News:MedX Pharmacy Offers Skin Care Tips 2
... has been an evident reduction in the breast cancer cases ... this, and one conceivable reason has particularly caught their attention. ... 2002. Whether mere reduction in HRT has brought out such ... has been an almost 7 percent reduction in the number ...
... people with history of unprotected sex to have an ... transmission.// The announcement being the first case of such ... Thursday uncovered two clusters of HIV infections, HIV-1 subtype ... government scientists. They said that both the clusters found ...
... it as a 'citizens raid', Bhopal gas tragedy survivors' ... sub-standard and expired drugs from two medical stores of ... ,"A joint team of four organisations, working for ... recovered many medicines that had crossed their expiry date," ...
... University of Pennsylvania Health System are starting a trial ... its electrical pulses// essentially short-circuit, referred to as atrial ... into with current therapies to cope with electrical rhythmic ... procedures, is that up until now, they’ve had to ...
... while ‘over the limit,’ but subsequently found to be below ... range of drugs, reveals research in Injury Prevention. ... testing in all drivers who are suspected of being over ... findings on 2000 blood and urine specimens taken from drivers ...
... The route to a man’s heart is through his stomach, they ... the kitchen? Food for thought, of course! Meanwhile, what could be ... the attention of the lady of the house, says a new ... embarked on a study of almost 200 British men and women, ...
Cached Medicine News:Health News:New Tool Being Tested to Halt Recurrence of Atrial Fibrillation 2Health News:One in Three Drivers Under ‘The Limit’ for Alcohol Still Test Positive for Dru 2Health News:How a Woman Holds Fort in Her Little Kingdom – The Kitche 2
... Restylane is a ... generated by,Streptococcus species of ... stabilized and suspended in ... = 7 and concentration ...
The HEMOCHRON Model 401 is a portable, single-well whole blood coagulation monitoring instrument. The 401 provides on-screen plasma equivalent PT and APTT test results....
Minimizes imperfections and reduces the visible appearance of cellulite and stretch marks. This formula refines uneven skin texture and improves skin firmness and elasticity to leave you with skin yo...
... delivers clinically proven aminophylline directly to the ... fat reduction with the aminophylline containing cream ... an increase in the firmness of the ... the skin where it causes the body ...
Medicine Products: